Vedolizumab-Associated Hypereosinophilia and Hepatoxicity

ABSTRACT Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab...

Full description

Saved in:
Bibliographic Details
Published inACG case reports journal Vol. 9; no. 11; p. e00905
Main Authors De Marco, Davide, Bessissow, Talat, Marcus, Victoria, Benmassaoud, Amine
Format Journal Article
LanguageEnglish
Published Maryland, MD Wolters Kluwer 01.11.2022
Subjects
Case Report
Liver
Online AccessGet full text

Cover

More Information
Summary:ABSTRACT Vedolizumab, which is approved for the treatment of ulcerative colitis, has been associated with drug-induced liver injury because of an unclear mechanism. We describe the case of a 29-year-old man who presented with abnormal liver enzymes and peripheral hypereosinophilia after vedolizumab initiation. A complete workup for causes of hepatitis and hypereosinophilia was negative, and liver biopsy showed signs compatible with drug-induced liver injury. After the withdrawal of vedolizumab, the patient's eosinophil count and liver enzymes normalized. As vedolizumab becomes more prominent, it is important to understand the potential side-effect profile of vedolizumab.
ISSN:2326-3253
2326-3253
DOI:10.14309/crj.0000000000000905